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Abstract. Similarity of skin cancer with many benign skin pathologies requires reliable methods to detect and
differentiate the different types of these lesions. Previous studies have explored the use of disparate optical
techniques to identify and estimate the invasive nature of melanoma and basal cell carcinoma with varying out-
comes. Here, we used a concerted approach that provides complementary information for rapid screening and
characterization of tumors, focusing on squamous cell carcinoma (SCC) of the skin. Assessment of in vivo auto-
fluorescence lifetime (FLT) imaging of endogenous fluorophores that are excitable at longer wavelengths
(480 nm) than conventional NADH and FAD revealed a decrease in the short FLT component for SCC compared
to normal skin, with mean values of 0.57 0.026 ns and 0.61 0.021 ns, respectively (p ¼ 0.004). Subsequent
systemic administration of a near-infrared fluorescent molecular probe in SCC bearing mice, followed by the
implementation of image processing methods on data acquired from two-dimensional and three-dimensional
fluorescence molecular imaging, allowed us to estimate the tumor volume and depth, as well as quantify
the fluorescent probe in the tumor. The result suggests the involvement of lipofuscin-like lipopigments and ribo-
flavin in SCC metabolism and serves as a model for staging SCC.© The Authors. Published by SPIE under a Creative Commons
Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its
DOI. [DOI: 10.1117/1.JBO.22.6.066007]
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1 Introduction
Skin cancer is the most common cancer worldwide with the
World Health Organization estimating 2 to 3 million cases
each year. The disease comprises many types, including basal
cell and squamous cell carcinoma (SCC), which are forms of
nonmelanoma skin cancer (NMSC). The incidence of NMSC
is increasing, underscoring the importance of early detection
and diagnosis.1–3 Skin cancer is often detected visually, followed
by the use of biopsy for histopathological validation. Visible
signs of skin cancer can include changes in skin color, rough-
ness, a raised area, or a wound that does not heal. However, the
disease can be more subtle, in some cases presenting as an area
that is pruritic with altered sensation.4 In a subset of cases, there
is no obvious border to a skin cancer tumor which can lead to the
incomplete resection that occurs in as high as 15% of cases.5
Because of the diverse appearance of skin cancers and the some-
times obscure tumor border, a reliable detection method would
be beneficial. The use of optical imaging methods to increase the
accuracy of identifying tumors and their boundaries is attractive
because of the low cost, portable instrumentation, and the ability
to provide real-time feedback.
Because SCC is on the surface of the body, imaging and ana-
lyzing a region of skin could prove effective in reliably identi-
fying the disease. Malignant tumors are known to induce
significant changes in the size of cellular organelles, pigmenta-
tion, and the concentrations or ratios of endogenous fluoro-
phores compared to normal skin. As a result, light scattering
and fluorescence intensity measurements have been used to
characterize healthy and pathologic skin conditions in small ani-
mals and humans.6–11 Autofluorescence imaging is widely used
to characterize skin tissue due to the presence of a hetero-
geneous mixture of endogenous fluorophores, including
NADH, elastin, collagen, and flavins.12 To minimize imaging
artifacts, improve the reproducibility and reliability of diagnos-
tic information, and reduce errors caused by the contribution of a
myriad of endogenous fluorophores to the intensity measure-
ments, autofluorescence lifetime (FLT) focusing on NADH
and FAD has been explored13,14 for melanoma15 and basal
cell carcinoma.16 Previous studies have demonstrated that fluo-
rescence lifetime imaging microscopy can be used to differen-
tiate NMSC from uninvolved tissue.16,17 However, SCC exhibits
a diverse array of gross pathological features, necessitating the
survey of a larger tissue area than what is typically accessible by
microscopic methods. In addition, recent studies have shown
that some endogenous fluorophores, such as lipofuscins, lipofus-
cin-like lipopigments, and riboflavin, enhance the intracellular*Address all correspondence to: Samuel Achilefu, E-mail: achilefus@mir.wustl
.edu
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fluorescence of malignant tumors upon excitation at 450 to
500 nm.18–20
For staging, knowing the extent of the penetration of the dis-
ease is important. Although the FLT can identify skin lesions,
visible light can only penetrate a few millimeters into the tissue,
limiting tissue analysis to superficial regions. Conversely, near-
infrared (NIR) light is less absorbed by the tissue and can pen-
etrate to greater depths, allowing the use of NIR fluorescent
molecular probes to differentiate tumors from healthy tissue
when they accumulate preferentially in the cancer.21,22 A variety
of methods are available for delivering the molecular probes to
tumors, including reliance on the enhanced permeation and
retention effect, conjugation to an antibody or a peptide that tar-
gets cancer cells, and constructing nanoparticles containing
tumor-homing moieties.23
In this study, we explored the use of in vivo FLT imaging of
biomarkers that are excitable at longer wavelengths than con-
ventional NADH and FAD for distinguishing NMSC from
surrounding uninvolved skin. Image analysis of fluorescence
intensity data from planar imaging and NIR fluorescence molecu-
lar tomography (FMT) allowed us to determine the tumor extent
and quantify the molecular probe concentration in SCC.
2 Methods
2.1 Animal Model Development
All studies were in compliance with the Washington University
Animal Welfare Committee’s requirements for the care and
use of laboratory animals in research. We used an orthotopic
model of SCC-12 (human cutaneous SCC) to develop methods
for skin cancer identification and characterization.24 SCC-12
cells were cultured using Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum and 1% penicillin
streptomycin in a humidified incubator at 37°C. We injected
2.5 × 106 cells into the intradermal compartment of 6-week
old female athymic nude mice (n ¼ 5) in the bilateral shoulder
and flank regions by placing the needle just below the surface of
the skin. Tumors were allowed to grow for 3 weeks before im-
aging. In some cases, the tumors did not graft, and these regions
were not included in the study.
2.2 Autofluorescence Imaging
FLT imaging was conducted using the Optix MX3 system (ART
Advanced Research Technologies, Montreal, California) with
excitation and emission wavelengths at 480 and 535 nm, respec-
tively. Full quantitative analysis was performed to obtain the
FLT for each pixel.
2.3 Near-Infrared Fluorescence In Vivo Imaging
Our lab has previously reported on an NIR fluorescent probe
that selectively accumulates in tumors in vivo.25 This probe,
cypate-peptide derivative (cypate-GRD), has demonstrated effi-
cacy in a number of different tumor types, but it has not yet been
explored in skin cancer. The compound was injected via the tail
vein, at a dose of 0.40 mg∕kg, suspended in 100 μL of phos-
phate-buffered saline. The injected amount was selected by
identifying a dose that would allow for adequate visualization of
the tumors without increasing the background signal. Animals
(n ¼ 4) were imaged at 24-h postinjection using the Pearl Small
Animal NIR fluorescence imaging system (LICOR Biosciences,
Nebraska), λex∕em 785∕820 nm. Fluorescence and reflectance
images were obtained using the FMT 4000 system (PerkinElmer,
Inc., Massachusetts) λex∕em 790∕ > 805 nm.
2.4 Near-Infrared Fluorescence Ex Vivo Imaging
Excised tumor tissues were flash-frozen in optimum cutting
temperature compound (Tissue Tek, California) and stored at
−20°C. The tumors were sliced at a thickness of 10 μm
(Cryocut 1800, Illinois). H&E staining of excised tumor and sur-
rounding tissues was used for histologic validation of tissue
types. Microscopy was performed with an Olympus BX51
upright microscope (Olympus America, Pennsylvania). An
NIR filter (U-N41130 Chroma Technology Corp, Vermont)
was used for excitation at 775 25 nm and emission at
845 27 nm.
2.5 Near-Infrared Tumor Characterization
Tumor volume was estimated using a gradient-based tumor vol-
ume algorithm.26 For depth estimation, we utilized the fluores-
cence and reflectance images obtained using the FMT system.27
We incorporated our fluorescence gradient-based approach to
the FMT method to define the tumor regions of interest (ROIs)
for analysis. The fluorescence wavelength was 810 nm (λ2), and
the reflectance wavelength was the excitation light wavelength
of 790 nm (λ1). The following equations were used to calculate
the depth as a function of the natural log of the ratio of the inten-
























EQ-TARGET;temp:intralink-;e004;326;294 lnðΓÞ ¼ m × dþ b; (4)
EQ-TARGET;temp:intralink-;e005;326;265d ¼ lnðΓÞ − b
m
; (5)
where Γ is the ratio of the fluorescence signal intensity to the
reflectance signal intensity, δ is the penetration depth, D is the
diffusivity based on the optical properties at each wavelength (λ1
and λ2), and d is the depth. The general form of Eq. (4) can be
rearranged and solved for depth using Eq. (5). The slope and
y-intercept were calculated as m and b, respectively.
The input tissue optical parameters for Eqs. (2) and (3), μα
and μ 0S, were estimated at our wavelengths of interest (790
and 810 nm) from a model developed by Jacques.28 Using
this model, we assumed the fraction of melanin as 3.8% for
mice (average for a light-skinned adult human) and the model
predicted μα790 ¼ 5.867, μα810 ¼ 5.208, μ 0S790 ¼ 14.142, and
μ 0S810 ¼ 12.941 cm−1. When these values were used in Eq. (1)
through Eq. (4), m ¼ −1.927 and b ¼ 0.098. We used these
parameters to solve for depth pixel-by-pixel using Eq. (5).
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Because this method was susceptible to variability in the y-inter-
cept value (b), the maximum spread of the depths within the
tumor region was used to represent the depth as opposed to
the absolute values obtained.
Three-dimensional (3-D) tumor images were obtained using
the FMT system with 2-mm source density. Reconstruction and
image analyses were performed using TrueQuant™ software
(PerkinElmer, Inc., Massachusetts). Fluorescence quantification
of our NIR fluorophore was based on a concentration calibration
using the calibration phantom provided with the system.
Rectangular prism ROIs were drawn around tumors of 3-D
reconstructed images, using the planar fluorescence images
for guidance.
3 Results and Discussion
We chose 480-nm excitation to image due to the abundance of
endogenous fluorophores, such as flavins, lipofuscins, and lip-
ofuscin-like, in this spectral range.19 FLT images of the tumor
regions and a skin region on the mouse flank were determined
[Fig. 1(a)]. Analysis of the fluorescence intensity decays for
each region indicated the presence of two different time con-
stants in the overall decay [Fig. 1(b)]. We found that a
Fig. 1 (a) Representative mouse images showing the lifetime of a tumor region and an uninvolved skin
region. A total of 5 mice with 14 tumors were analyzed. (b) Representative FLT decay showing a steep
initial decay then a slower decay at longer times. (c) Average FLT long component for skin and tumor
showing no difference. (d) Average FLT short component for skin and tumor showing a lower lifetime for
the tumor, p ¼ 0.004. (e) Lifetime maps for each pixel for tumors and skin. Tumors exhibited shorter
lifetimes with the more central region containing the shortest lifetimes. Tumor locations are indicated
as left flank (LF), left shoulder (LS), right flank (RF), and right shoulder (RS). (f) Histogram of long lifetime
component for each pixel showing no difference. (g) Histogram for short lifetime component showing that
shorter values are unique to tumors. (h) ROC curve showing the sensitivity and specificity for tumor iden-
tification using different short lifetime thresholds (the data point labels).
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single-component fit did not fit the shape of the decay. To most
accurately represent the decay, a fit that represented each of the
fluorescence molecules present would be ideal, however, less
practical. By using a two-component fit, we were able to
adequately fit the FLT decay; however, some variation between
samples remained due to the heterogeneous composition of the
tissue itself.
Because we were interested in understanding if FLT could be
applied to a macroscopic image of the tumor, we compared the
average values of our ROIs. Our assessment of the average FLT
of the long component for each ROI did not reveal any differ-
ence between the tumors and skin regions [Fig. 1(c)]. In con-
trast, the analysis of the average lifetime of the short
component revealed a difference between regions containing
tumors and skin, with a mean lifetime of 0.57 0.026 ns
and 0.61 0.021 ns, respectively [Fig. 1(d)]. This difference
was significant at p ¼ 0.004. One of the short component
FLT values was lower than the rest in the tumor group. To ensure
that the significant difference between the skin and tumor was
not due to this point, we recalculated the data for statistical com-
parison. The p-value with this point removed was also signifi-
cant at p ¼ 0.002. We attributed this FLT value to the often-
observed heterogeneity in biological assays or the redox state
of the cancer at the time of measurement.
We created lifetime pixel maps using the short lifetime, and
we observed that the shorter lifetimes were associated with the
more central regions of the tumors [Fig. 1(e)]. Short lifetime
values within the tumors that were closer to the skin values
were located around the edges, which implies that these
areas were more similar to the surrounding skin tissue. Using
each of the pixel values to create histograms for the long and
short components of the lifetime, we confirmed that the
long lifetimes had the same distribution for tumors and skin,
while the short lifetimes exhibited values that were unique for
the tumors [Figs. 1(f) and 1(g)]. These data demonstrate a
spatial distribution of the short lifetime values within the
ROIs.
We investigated the sensitivity and specificity of using the
short lifetime component to delineate tumors from skin by set-
ting a threshold [Fig. 1(h)]. The mean short lifetime for each
ROI was more sensitive than specific at all thresholds because
the receiver operating characteristic (ROC) curve consistently
favored higher sensitivity values than the corresponding speci-
ficity value for each point. The spatial information appears to
have an impact on the short lifetime, with shorter lifetimes
more centrally located within the tumor. Hence, combining
the short lifetime data with spatial information could enhance
both sensitivity and specificity of the method. Literature reports
have identified lipofuscins, lipofuscin-like lipopigments, and
riboflavins as the major fluorescent species at the wavelengths
we have explored.18–20 These biomolecules are actively involved
in cellular metabolism. Miranda-Lorenzo et al.20 identified
riboflavin as the primary autofluorescent moiety in the
480-∕535-nm excitation/emission region. The authors attributed
the increase in riboflavin autofluorescence to cells with high
proliferation potential. However, we do not know at his time
how the metabolic processes in the tumor affected the short
FLTs in cancer and healthy skin. Probably, response of the
endogenous fluorophores to pH, oxygenation status, and
redox state of cancer differs significantly from those of healthy
tissue.
The autofluorescence method enabled us to image the super-
ficial aspects of the tumors. However, the shallow depth penetra-
tion of visible light in tissue limited the information that we
could obtain. To gain insight into deeper tumor characteristics,
we injected an NIR fluorophore and allowed it to accumulate in
the tumors [Fig. 2(a)]. Quantification of the in vivo fluorescence
intensity showed that the tumors exhibited a higher signal
(0.42 0.044) than the skin regions (0.26 0.012), p ¼ 0.003.
[Fig. 2(b)] After concluding the in vivo study, we euthanized a
mouse and confirmed the presence of our fluorophore in the
tumor tissue. Figures 2(c) and 2(d) show the tumor histology
and fluorophore distribution within the tumor, respectively. A
section of the tumor was magnified to visualize the fluorophore
along with cells within the tumor [Fig. 2(e)].
We explored the tumor extent using the NIR signal as a
guide. Figure 3(a) shows a representative NIR fluorescence
image of a tumor-bearing mouse captured using a planar imag-
ing system. Images were analyzed for tumor volume using a
previously described gradient-based approach26 and are shown
for each tumor [Fig. 3(b)]. Tumors that had inadequate contrast
for the algorithm to calculate a volume were represented with a
negative value in the plot. The tumor volume estimation method
used the equation V ¼ 0.5 × L ×W2, where V is the tumor vol-
ume, L is the tumor length, andW is the tumor width. This equa-
tion used the tumor width as a surrogate for understanding the
tumor depth. Because of this assumption, the translation of this
approach to broader applications outside of small animal imag-
ing is limited. To understand the extent of the tumor more
directly, the depth dimension would need to be calculated rather
than using the width as a surrogate for depth.
Fig. 2 (a) Representative image of NIR fluorescent probe in vivo
showing tumor contrast (white arrows). (b) Quantification of skin
regions versus tumor regions with tumors exhibiting higher fluores-
cence. A total of three tumor regions and three skin regions were
analyzed. (c) H&E staining of an SCC tumor was analyzed at 4×mag-
nification. (d) Fluorescence distribution of the fluorescent probe within
the tumor. (e) 40×magnified view of fluorescent probe with cells within
the tumor.
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To accomplish depth estimation, we used a fluorescence-to-
reflectance ratio method to determine the extent of tumor pen-
etration. Swartling et al.29 used this approach to calculate the
depth for a point-like fluorescence source, and Kolste et al.27
expanded this method to depth estimation using planar imaging.
Using the FMT imaging system, we obtained fluorescence
[Fig. 3(c)] and reflectance [Fig. 3(d)] images of the mice. We
defined tumor versus nontumor ROIs using the same gra-
dient-based approach for tumor isolation that we used to obtain
the tumor volume. For pixels defined as tumor, we divided the
fluorescence signal by the reflectance signal and then utilized
the natural log of the ratio for the depth estimation. This method
required knowledge of the tissue optical parameters at the wave-
lengths of interest. We estimated these values using a previously
developed model for tissue property estimation as a function of
wavelength.28 We found that the depth estimation method was
very sensitive to the parameters that dictated the y-intercept
value of the curve fit, which were in turn impacted by the optical
parameters selected. To stabilize the depth estimation output, we
calculated the difference in depth between the maximum and
minimum depth values within the tumor ROI and recorded this
value as the estimated depth [Fig. 3(e)]. Saturated pixels were
excluded from the analysis, and tumors that returned no depth
values were represented as negative values in the plot. The
method did not return values in two tumors [M1 left flank
(LF) and M5 left shoulder (LS)] due to image saturation and
one tumor (M3 LS) due to inadequate fluorescence signal.
The estimated tumor depths were compared to the caliper mea-
sured tumor depths [Fig. 3(f)]. The red line shows the ideal case
of correlation between the method estimates and the measured
depths. While there was some difference between the estimated
result and the idealized values, the average deviation from the
caliper measurement was 1.244 mm down to an imaging
depth of 8 mm.
We then employed 3-D NIR tomography to understand the
extent of tumors. Figures 4(a) and 4(c) show a mouse with the 3-
D distribution of the NIR fluorescent probe in both the coronal
and sagittal views. Although the tumors were visible, there was
also high signal from the intestinal tract as mouse chow has NIR
fluorescence. To remove background fluorescence, ROIs were
drawn around each tumor [Figs. 4(b) and 4(d)]. Figure 4(e)
shows the fluorophore concentration in each tumor based on
the ROI volume, and Fig. 4(f) shows the total amount of the
fluorophore within the ROI. We compared the estimated
tumor volume to the total fluorophore amount to determine if
the probe accumulation was related to tumor volume [Fig. 4(g)].
We found that they were correlated with a Spearman’s correla-
tion coefficient of 0.82, p ¼ 0.003. However, the probe accu-
mulation was not correlated with the estimated tumor depth
[Fig. 4(h)].
Fig. 3 (a) Representative gradient-based tumor volume algorithm NIR fluorescence images showing the
tumor outline used to estimate the tumor volume. (b) Estimated tumor volume by mouse and tumor (M2
was not injected with the fluorescent probe). A total of 4 mice and 13 tumors were analyzed, 11 tumors
returned results. Tumor locations are indicated by LF, LS, RF, and RS. (c) Fluorescence image used for
the fluorescence–reflectance depth imaging analysis. (d) Reflectance image used for the fluorescence–
reflectance depth imaging analysis. (e) Depth estimates using the fluorescence–reflectance method by
mouse and by tumor. A total of 4 mice and 13 tumors were analyzed, 10 tumors returned results.
(f) Estimated versus measured depth for each of the tumors where a depth estimate was successfully
obtained.
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4 Conclusions
Noninvasive imaging has an advantage over direct tumor meas-
urement and evaluation in that it allows for understanding the
functional and structural behavior of a tumor. Imaging also
allows for the retrospective analysis of images to extract addi-
tional information and track therapeutic efficacy. We evaluated
SCC using a number of imaging modalities to both identify and
characterize the disease in vivo. The FLT imaging results were
consistent with previous work which found that basal cell car-
cinoma, another form of NMSC, had shorter FLTs as compared
to uninvolved tissue using NADH and FAD as biomarkers.16
Although the differences in the short FLT between cancer
and healthy skin were statistically significant and sufficient to
distinguish tumor from surrounding tissue, practical application
of the technique would require the development of optical sys-
tems with high temporal and spatial resolution to improve the
detection accuracy. A key component to the successful imple-
mentation of this approach is to establish a reliable FLT thresh-
old for specific tumor types. With recent advances in the
development of devices that allow for in vivo assessment of
FLT,30 we expect that our findings can be used to identify tumor
versus uninvolved tissue in vivo.
We used an NIR fluorescent probe to capture the extent of the
tumor by estimating the tumor volume, which can be used to
track a therapeutic response. Further, we demonstrated that NIR
fluorescence planar imaging could be used to estimate tumor
depth with relative agreement to the measured values. The rel-
ative ease of our method could overcome the challenges of
assessing tumor depth noninvasively. Finally, we demonstrated
the ability of FMT to capture the amount of a fluorescent probe
in the tissue. By incorporating fluorescent probes into drugs, or
the use of drugs that emit light, FMT could be used to track the
amount of a drug that reaches a target, particularly for therapies
such as photodynamic therapy, where the amount of drug
present can impact the desired light dose within a region.
The summation of this work provides a framework for the
optical interrogation of skin cancer. Each of our methods was
conducted in vivo in a living mouse, which makes it ideal for
longitudinal studies tracking therapeutic response. Use of
FLT allowed us to identify SCC tumors without the need
for an exogenous imaging agent. Because light-based methods
are cost effective and can be implemented in real time, the opti-
cal imaging techniques described in this paper can be used to
screen and stage NMSC lesions in human subjects. Our results
suggest that the integration of different optical methods could
improve the accuracy of identifying, tracking, and phenotyping
tumors, in hopes of improving existing diagnoses and therapies.
This study provides a model for screening SCC with endog-
enous fluorophores, staging the disease with exogenous fluores-
cent molecular probes, and quantifying the amount of a drug-








































































































(a) (b) (c) (d)
Fig. 4 (a) 3-D FMT image showing whole body distribution of the NIR fluorescence signal. Tumors exhib-
ited a higher uptake than the surrounding tissue. The mouse digestive tract was visible due to the fluo-
rescence from the chow. (b) Tumors enclosed in ROIs to remove fluorescence from the digestive tract.
The concentration of fluorophore shown in 3-D within the tumor ROIs. (c) Sagittal view of NIR fluores-
cence signal. (d) Sagittal view of tumors in ROIs. (e) Quantification of fluorophore amount per voxel in
each tumor ROI. A total of 4 mice and 12 tumors were analyzed. Tumor locations are indicated by LF, LS,
RF, and RS. (f) Quantification of total fluorophore amount in each ROI. (g) Estimated tumor volume ver-
sus fluorophore amount showing a correlation, p ¼ 0.003. A total of 11 tumors had values for both the
fluorophore amount and estimated tumor volume. (h) Estimated tumor depth versus fluorophore amount
not correlated. A total of 10 tumors had values for both the fluorophore amount and estimated tumor depth.
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